This is a Validated Antibody Database (VAD) review about pig BCL2L1, based on 5 published articles (read how Labome selects the articles), using BCL2L1 antibody in all methods. It is aimed to help Labome visitors find the most suited BCL2L1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
BCL2L1 synonym: bcl-2-like protein 1; anti-apoptotic Bcl-xL; apoptosis regulator Bcl-X; bcl2-L-1

Invitrogen
mouse monoclonal (2H12)
  • western blot; human; fig 2
In order to identify and characterize a new compound that targets Bcl-XL/Bcl-2, Invitrogen BCL2L1 antibody (Invitrogen, AHO0222) was used in western blot on human samples (fig 2). Autophagy (2010) ncbi
mouse monoclonal (2H12)
  • immunohistochemistry - paraffin section; human
In order to identify prognostic biomarkers for complex karyotype soft tissue sarcoma, Invitrogen BCL2L1 antibody (Invitrogen, 2H12) was used in immunohistochemistry - paraffin section on human samples . Ann Oncol (2010) ncbi
mouse monoclonal (2H12)
  • western blot; human
In order to examine the hepatotoxicity of TRAIL/bortezomib cotreatment, Invitrogen BCL2L1 antibody (Biosource, 2H12) was used in western blot on human samples . Hepatology (2007) ncbi
mouse monoclonal (2H12)
  • immunocytochemistry; rat; 1:100; fig 1
In order to elucidate the role of Bcl-x(S) in nerve growth factor-inhibitable apoptosis, Invitrogen BCL2L1 antibody (Zymed, 2H12) was used in immunocytochemistry on rat samples at 1:100 (fig 1). Exp Cell Res (2004) ncbi
mouse monoclonal (2H12)
  • immunohistochemistry; human; 1:150; fig 1-4
In order to study the role of various bcl-2 family molecules in the regulation of apoptosis and the progression of urothelial cancer, Invitrogen BCL2L1 antibody (Zymed Laboratories, clone 2H12) was used in immunohistochemistry on human samples at 1:150 (fig 1-4). Eur Urol (2002) ncbi
Articles Reviewed
  1. Tian S, Lin J, Jun Zhou J, Wang X, Li Y, Ren X, et al. Beclin 1-independent autophagy induced by a Bcl-XL/Bcl-2 targeting compound, Z18. Autophagy. 2010;6:1032-41 pubmed publisher
  2. Lahat G, Tuvin D, Wei C, Wang W, Pollock R, Anaya D, et al. Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. Ann Oncol. 2010;21:1112-20 pubmed publisher
  3. Koschny R, Ganten T, Sykora J, Haas T, Sprick M, Kolb A, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 2007;45:649-58 pubmed
  4. Lindenboim L, Schlipf S, Kaufmann T, Borner C, Stein R. Bcl-x(S) induces an NGF-inhibitable cytochrome c release. Exp Cell Res. 2004;297:392-403 pubmed
  5. Korkolopoulou P, Lazaris A, Konstantinidou A, Kavantzas N, Patsouris E, Christodoulou P, et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol. 2002;41:274-83 pubmed